Delving into the Latest Updates on PepGNP-SARSCoV2(Emergex Vaccines Holding) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms-

Target

SARS-CoV-2 antigen

Mechanism

SARS-CoV-2 antigen inhibitors

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

COVID-19

Inactive Indication-

Originator Organization

Gylden Pharma Ltd.Startup

Active Organization

Gylden Pharma Ltd.Startup

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

This trial is Stage 2 of a 2-part adaptive trial. The study aims to investigate the safety of 2 doses of a T-cell priming specific cocktail of Coronaviruses peptides mounted on a gold nanoparticle.
Note: Stage 1 of the 2-part adaptive trial, testing a specifically selected mix of Dengue virus peptides, commenced Aug 2021. This is now in follow up (NCT04935801).

Start Date10 Jan 2022

Sponsor / Collaborator

Gylden Pharma Ltd.Startup

[+1]

100 Clinical Results associated with PepGNP-SARSCoV2(Emergex Vaccines Holding)

Login to view more data

100 Translational Medicine associated with PepGNP-SARSCoV2(Emergex Vaccines Holding)

Login to view more data

100 Patents (Medical) associated with PepGNP-SARSCoV2(Emergex Vaccines Holding)

Login to view more data

100 Deals associated with PepGNP-SARSCoV2(Emergex Vaccines Holding)

Login to view more data